Precigen, Inc. - Common Stock (NQ:PGEN)

7.740 -0.800 (-9.37%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Precigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

August 25, 2026

From Precigen, Inc.

Via ACCESS Newswire

Precigen (PGEN) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

PAPZIMEOS revenue surged 145.8% sequentially as company posts first profitable quarter.

Via The Motley Fool

Topics Earnings

Precigen Q2 Earnings Call Highlights ↗

August 04, 2026

Precigen (NASDAQ:PGEN) reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy’s August 2025...

Via MarketBeat

Topics Earnings

What's going on in today's after hours session ↗

August 04, 2026

Via Chartmill

Precigen Inc (NASDAQ:PGEN) Flashes Perfect Technical Rating and Explosive Sales Growth in Minervini Screen ↗

July 08, 2026

Via Chartmill

Precigen Inc (NASDAQ:PGEN) Stock Surges on Narrower Loss and Commercial Transition After FDA Approval ↗

March 25, 2026

Via Chartmill

Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet? ↗

December 02, 2025

Via The Motley Fool

What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors? ↗

July 15, 2026

Focused on gene and cellular therapies, this biotech firm reported a notable insider sale amid a year of rapid share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

June 15, 2026

Via ACCESS Newswire

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares? ↗

June 12, 2026

Focused on gene and cell therapies, this biotech innovator reported a notable insider sale amid a year of exceptional share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Precigen Q1 Earnings Call Highlights ↗

May 14, 2026

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025. On...

Via MarketBeat

Topics Earnings

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Precigen (PGEN) Q1 2026 Earnings Transcript ↗

May 13, 2026

Precigen (PGEN) Q1 2026 Earnings Transcript

Via The Motley Fool

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

April 07, 2026

Via ACCESS Newswire

These Analysts Boost Their Forecasts On Precigen Following Q4 Results ↗

March 26, 2026

Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating estimates but sales of $4.565 million falling short.

Via Benzinga

Thursday's session: gap up and gap down stocks ↗

March 26, 2026

Via Chartmill

These stocks that are showing activity before the opening bell on Thursday. ↗

March 26, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

March 25, 2026

Via Chartmill

Precigen (PGEN) Q4 2025 Earnings Call Transcript ↗

March 25, 2026

Precigen (PGEN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Inside One Fund's $21 Million Bet on Hilton Grand Vacations Stock ↗

January 24, 2026

This vacation ownership firm serves over 700,000 members and generates recurring revenue from real estate, financing, and resort operations.

Via The Motley Fool

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 14, 2025

Via Benzinga

Precigen Inc (NASDAQ:PGEN) Q3 2025 Earnings: Revenue Soars But Wider Loss Dampens Investor Sentiment ↗

November 13, 2025

Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS.

Via Chartmill

Precigen (PGEN) Q3 2025 Earnings Call Transcript ↗

November 13, 2025

Precigen (PGEN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Exploring Precigen's Earnings Expectations ↗

November 12, 2025

Via Benzinga

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares ↗

November 01, 2025

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares

Via The Motley Fool

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗

September 07, 2025

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Via The Motley Fool

Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗

September 03, 2025

Via Benzinga

Unusual volume stocks in Friday's session ↗

August 22, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

Unusual volume stocks in Thursday's session ↗

August 21, 2025

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.